2024 World Conference on Lung Cancer (WCLC) - Posters-P3.06E.02 Serum NY-ESO-1 And XAGE1 Antibodies Are Diagnostic and Cancer-Specific Immunomonitoring Markers in NSCLC

P3.06E.02 Serum NY-ESO-1 And XAGE1 Antibodies Are Diagnostic and Cancer-Specific Immunomonitoring Markers in NSCLC

Pdf Summary

This retrospective study investigates the role of antibodies against NY-ESO-1 and XAGE1 cancer/testis antigens as diagnostic and immuno-monitoring markers in non-small cell lung cancer (NSCLC). Conducted at Kawasaki Medical School Hospital, it included 543 NSCLC patients diagnosed between 2015 and 2023, covering various treatments such as surgery, chemotherapy, targeted therapy, and immune checkpoint inhibitors (ICI). NY-ESO-1 and XAGE1 antigens are known for their cancer-specific expression and ability to elicit immune responses. NY-ESO-1 is broadly expressed across multiple cancers, while XAGE1 is particularly noted in lung adenocarcinoma.<br /><br />The study found that antibodies to these antigens were present in about 20% of NSCLC patients, especially noting a higher incidence of XAGE1 antibodies in lung adenocarcinoma cases. This suggests these antibodies could serve as diagnostic markers for NSCLC. The study also indicated that the levels of these antibodies correlate with clinical responses to various treatments, supporting their role as immuno-monitoring markers. <br /><br />For the quantitative measurement of these antibodies, an automated immunoassay (HISCL) was developed, improving the reproducibility and application of these findings in clinical settings.<br /><br />The research underscores the potential of using NY-ESO-1 and XAGE1 antibodies not only for diagnosing NSCLC but also for tracking treatment responses, particularly in relation to ICI and target therapies. Existing treatments can be potentially evaluated and optimized by monitoring these antibody levels, offering a personalized approach to therapy management in NSCLC cases. This represents a significant advancement in the fields of oncology diagnostics and patient-specific treatment monitoring.

Asset Subtitle

Mikio Oka

Meta Tag

Speaker Mikio Oka

Topic Pathology & Biomarkers

Keywords

NSCLC

antibodies

NY-ESO-1

XAGE1

diagnostic markers

immuno-monitoring

lung adenocarcinoma

immune checkpoint inhibitors

automated immunoassay

personalized therapy